Global Leading Market Research Publisher QYResearch announces the release of its latest report “Animal Regenerative Medicine and Stem Cell Therapy – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Animal Regenerative Medicine and Stem Cell Therapy market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Animal Regenerative Medicine and Stem Cell Therapy was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of % from 2026 to 2032. Animal stem cell therapy is a usage of animal’s stem cell to treat a disease or disorder. The ability of stem cell is to divide and differentiate into a cell with specialized function useful for repairing body tissues damaged by injury or disease. The animal stem cell therapy process involves three steps which include collection of stem cell sample from animals and preparing the sample to concentrate the stem cells. Finally, the therapy includes transferring the stem cells into the injured site for treatment. Animal stem cell therapy increases the expectancy of life in animals with no side effects. It is available for the treatment of arthritis, degenerative joint disorders, tendon, and ligaments injuries in animals. Stem cell therapy is most often used to treat dogs, cats, and horses. But recent developments made it possible to use animal stem cell therapy in tiger, pig, etc. Present animal stem cell therapy is studied in treatments of the inflammatory bowel, kidney, liver, heart and immune-mediated diseases respectively.
Addressing Core Canine Feline Equine Osteoarthritis, Tendon/Ligament Injury, and Regenerative Medicine Pain Points
Veterinarians (small animal, equine), veterinary hospitals, and pet owners face persistent challenges: osteoarthritis (OA) affects 20-40% of dogs and 30-60% of cats (age 8+), causing chronic pain and mobility loss. Tendon/ligament injuries (cranial cruciate ligament (CCL) rupture, Achilles tendon, suspensory ligament desmitis) in horses and dogs have limited healing capacity (scar tissue, re-injury risk). Traditional treatments (NSAIDs, corticosteroids, surgery) manage symptoms but do not regenerate tissue. Animal regenerative medicine and stem cell therapy—adipose-derived mesenchymal stem cells (MSCs) or bone marrow-derived MSCs injected into injured joints, tendons, or ligaments—have emerged as the solution for tissue regeneration, reduced inflammation, and improved function. However, product selection is complicated by two distinct animal segments: dogs stem cell therapy (small animal, companion animal) versus horses stem cell therapy (equine, sport horse, racehorse) versus others (cats, tigers, pigs, livestock). Over the past six months, new FDA/CVM guidance on veterinary stem cell products, clinical studies for canine osteoarthritis, and equine tendon/ligament regeneration have reshaped the competitive landscape.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5732440/animal-regenerative-medicine-and-stem-cell-therapy
Key Industry Keywords (Embedded Throughout)
- Animal regenerative medicine
- Stem cell therapy dogs
- Horses arthritis tendon
- Veterinary hospital research
- Mesenchymal stem cells
Market Landscape & Recent Data (Last 6 Months, Q4 2025–Q1 2026)
The global animal regenerative medicine and stem cell therapy market is fragmented, with a mix of veterinary stem cell companies and animal health specialists. Key players include Ardent Animal Health (US), VetStem (US), Medrego (US), Vetbiologics (US), Vetherapy (US), Celavet (US), Magellan Stem Cells (US), Animal General (US), Stem Care Company (US), Animal Cell Therapies (US), Cell Therapy Sciences (US), and Animacel (US).
Three recent developments are reshaping demand patterns:
- FDA/CVM guidance on veterinary stem cell products (2025) : US FDA Center for Veterinary Medicine (CVM) issued guidance on regulatory pathway for animal stem cell products (minimally manipulated, homologous use). Regulatory clarity expanded market adoption.
- Canine osteoarthritis clinical studies: Multiple clinical trials (2024-2025) for canine OA (hip, elbow, stifle) with intra-articular MSC injections showing pain reduction (30-50%) and improved mobility (force plate gait analysis). Canine OA segment grew 12-15% in 2025.
- Equine tendon/ligament regeneration: Racehorse (thoroughbred, quarter horse) and sport horse (dressage, jumping, eventing) tendon injuries (superficial digital flexor (SDFT), deep digital flexor (DDFT), suspensory ligament). Equine stem cell therapy segment grew 10-12% in 2025.
Technical Deep-Dive: Dogs vs. Horses Stem Cell Therapy
- Dogs Stem Cell Therapy (small animal, companion animal). Advantages: larger market (90 million pet dogs in US, 150M in China, 100M in Europe), osteoarthritis (hip, elbow, stifle, shoulder, carpus), tendon/ligament (CCL, Achilles), inflammatory bowel disease (IBD), kidney/liver disease. A 2025 study from the American College of Veterinary Surgeons (ACVS) found that intra-articular MSC injections (adipose-derived) reduce canine OA pain by 40-60% at 6 months. Disadvantages: smaller animal (10-50kg), lower revenue per case ($1,000-3,000 vs. $3,000-10,000 for horses). Dogs accounts for approximately 60-65% of animal regenerative medicine market volume (largest segment), dominating companion animal veterinary hospitals.
- Horses Stem Cell Therapy (equine, sport horse, racehorse). Advantages: higher revenue per case ($3,000-10,000), athletic performance (racehorse, dressage, jumping, eventing), tendon injuries (SDFT, DDFT, suspensory ligament), osteoarthritis (fetlock, stifle, hock). Disadvantages: smaller market (10M horses globally vs. 500M dogs), longer recovery time (6-12 months). Horses accounts for approximately 30-35% of market volume, dominating equine sports medicine and performance horse rehabilitation.
User case example: In November 2025, a veterinary referral hospital (canine OA, 500 cases/year) published results from using adipose-derived MSC (mesenchymal stem cell) therapy for canine hip osteoarthritis (OA). The 12-month study (completed Q1 2026) showed:
- Stem cell source: adipose-derived (autologous, from patient’s fat).
- Delivery: intra-articular injection (hip joint).
- Pain reduction (CBPI score): 50% reduction at 6 months (60 → 30).
- Mobility improvement (force plate gait analysis): 40% improvement (peak vertical force).
- Cost per treatment: $1,500 (dog) vs. $500/year (NSAIDs) (3x premium). Payback period (pain relief + reduced NSAID side effects): 6 months.
- Decision: Stem cell therapy for canine OA; corticosteroids/NSAIDs for mild OA.
Industry Segmentation: Discrete vs. Continuous Manufacturing
- Animal stem cell therapy services (adipose collection, MSC isolation/expansion, quality control (viability, sterility, potency), injection) are service-based (autologous, patient-specific). Production volume: thousands to tens of thousands of treatments annually.
- Allogeneic stem cell products (off-the-shelf, donor-derived) are batch.
Exclusive observation: Based on analysis of early 2026 product launches, a new “allogeneic canine MSC product” (off-the-shelf, no surgery for fat collection) is emerging for canine OA. Traditional stem cell therapy requires liposuction/fat harvest (anesthesia, incision). Allogeneic MSCs (VetStem, Medrego, Celavet) are cultured from donor dogs, cryopreserved, and injected without harvest procedure. Allogeneic products command 20-30% premium ($2,000-3,000 vs. $1,500-2,000) and target elderly dogs (anesthesia risk) and owners preferring less invasive procedure.
Application Segmentation: Veterinary Hospitals, Research Organizations
- Veterinary Hospitals (small animal (dogs, cats), equine (horses), specialty referral hospitals) accounts for 70-75% of animal regenerative medicine and stem cell therapy market value (largest segment). Autologous and allogeneic. Growing at 10-12% CAGR.
- Research Organizations (academic veterinary schools, translational medicine, preclinical studies) accounts for 25-30% of value. Growing at 8-10% CAGR.
Strategic Outlook & Recommendations
The global animal regenerative medicine and stem cell therapy market is projected to reach US$ million by 2032, growing at a CAGR of %.
- Veterinarians (small animal, canine) : Adipose-derived MSC therapy for canine osteoarthritis (hip, elbow, stifle), tendon/ligament (CCL, Achilles), inflammatory bowel disease (IBD). Autologous (harvest from patient) or allogeneic (off-the-shelf) options.
- Equine veterinarians: MSC therapy for equine tendon/ligament injuries (SDFT, DDFT, suspensory ligament), osteoarthritis (fetlock, stifle, hock). Higher revenue per case ($3,000-10,000) for racehorse and sport horse rehabilitation.
- Veterinary hospitals: Offer stem cell therapy as advanced regenerative medicine service (differentiation from primary care). Point-of-care systems (stem cell processing kit) for same-day treatment.
- Manufacturers (Ardent, VetStem, Medrego, Vetbiologics, Vetherapy, Celavet, Magellan, Animal General, Stem Care, Animal Cell Therapies, Cell Therapy Sciences, Animacel): Invest in allogeneic MSC products (off-the-shelf, no harvest procedure), point-of-care stem cell processing systems (same-day treatment), and clinical studies for FDA/CVM approval. Equine (tendon/ligament) and canine (osteoarthritis) primary targets.
For canine, equine, and feline osteoarthritis, tendon/ligament injuries, and inflammatory diseases, animal regenerative medicine and stem cell therapy (adipose-derived or bone marrow-derived MSCs) provides tissue regeneration, pain reduction, and improved mobility. Dogs dominate companion animal segment; horses for equine sports medicine. Allogeneic (off-the-shelf) products emerging. FDA/CVM guidance and clinical studies drive adoption.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
